All News

#JulyIssue | This #Review provides an overview of the immunological, clinical and pathophysiological features of anti-citrullinated protein antibodies in #RheumatoidArthritis Check it out here: https://t.co/dzMHF9ETyu https://t.co/hRzkLp6K9g

Links:

NatRevRheumatol NatRevRheumatol ( View Tweet)
#JulyIssue | This #Review provides an overview of the immunological, clinical and pathophysiological features of anti-citrullinated protein antibodies in #RheumatoidArthritis Check it out here: https://t.co/dzMHF9ETyu https://t.co/hRzkLp6K9g

Links:

NatRevRheumatol NatRevRheumatol ( View Tweet)
RT: @aurelierheumo TOLERA trial in RA RTX/ABA sequence versus RTX alone 10pts each group Primary outcome was ambitious: ACPA seroconversion No difference between ttmts (and also no seroconversion) No diff in disease activity No diff in ACPA change wt wk52 OP0069 #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

pills-14550__180_0.jpg

Factors Affecting Hydroxychloroquine Adherence

d Jack Cush, MD

A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. 

Read Article
TARGET compared triple DMARD to TNFi in 122 RA pts and association with CV risk. In a subanalysis they found no correlation between change in lipid measurements and change in vascular inflammation by FDG-PET. https://t.co/0HKogmdRGH https://t.co/cD7UVTgTQ3

Links:

Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. https://t.co/rNOARWzEcI https://t.co/xebXgsouta

Links:

Dr. John Cush RheumNow ( View Tweet)
Is Rheumatoid Arthritis Preventable? Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. https://t.co/KmAFGwx414 https://t.co/ag5W9j9Kky

Links:

Dr. John Cush RheumNow ( View Tweet)
mtx.png (keep)

No Risk of Interstitial Lung Disease with Methotrexate Use

d Jack Cush, MD

JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).

Read Article
"AMPLIFIED study: abatacept vs adalimumab in RF+ACPA+ early RA Not a single blink of difference. Maybe for high CCP titre but the inverse for low CCP. Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007

Dr. John Cush RheumNow ( View Tweet)

Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020

Dr. John Cush RheumNow ( View Tweet)

BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1

Links:

Dr. John Cush RheumNow ( View Tweet)
holding hands together support frail

Is Rheumatoid Arthritis Preventable?

d Jonathan Kay, MD

Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without visible joint swelling.

Read Article
The path to new technologies in rheumatology must be beset with caution https://t.co/rostCE3UFT https://t.co/bn352RmrN8

Links:

Dr. John Cush RheumNow ( View Tweet)
RA: update for women of child bearing potential (and men!) Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients. https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult-to-treat Rheumatoid Arthritis: Validation of the EULAR Definition Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria. https://t.co/oc3Aj60KsM https://t.co/40FMjbKEHF

Links:

Dr. John Cush RheumNow ( View Tweet)
lightbulbs

The path to new technologies in rheumatology must be beset with caution

d David Liew, FRACP

As we have incorporated technology into our workflows, and consequently saved lives and suffering, we have balanced our excitement about progress with proof that incremental advances can truly deliver benefit. it is easy to let promise carry our caution away - and while most of the time such advances come in a vetted package, which we can consume without concern, conference abstracts come raw. This is the necessary ingredient to a platform which allows for bold ideas and innovation, but for that reason it is not such a curated space. At EULAR 2024, we saw the usual mix of bright, raw ideas on the poster floor emblematic of this paradigm.

Read Article
Proportion of ILD patients on IS drugs has massively increased over time! Also good to see practices are changing & MTX is slowly creeping in Anna Maria Hoffmann-Vold, ILD management session #EULAR2024 @AurelieRheumo https://t.co/npa8O7g7l8
Dr. John Cush RheumNow ( View Tweet)
How good are we at picking up depression in RA patients? In this Polish registry: - 1.8% had depression diagnosis - 21% had low mood on HAQ & depression has real correlates with disease activity. Plenty to think about with truly holistic RA care! #EULAR2024 POS1045 @drdavidliew https://t.co/ArfqHCKxhz
Dr. John Cush RheumNow ( View Tweet)
Difficult-to-treat RA: are we any closer to predicting who is at risk? 4 years ago EULAR published its definition of D2T RA. This marked a formal recognition of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic. https://t.co/kQJeUiRNtY https://t.co/xJEVihBMfm

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.